TCR2 Therapeutics Inc. announced it has entered into a Cooperative Research and Development Agreement with NCI to collaborate on the use of TCR2’s proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in the Company’s ongoing phase I/II trial of TC-210.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
